Vincent Bordas
Novartis (China)(CN)
Publications by Year
Research Areas
Fibroblast Growth Factor Research, Wnt/β-catenin signaling in development and cancer, Epigenetics and DNA Methylation, Hippo pathway signaling and YAP/TAZ, Cell Adhesion Molecules Research
Most-Cited Works
- → Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase(2011)487 cited
- → FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor(2012)360 cited
- → 6-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3)(2003)111 cited
- → 5-Aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3)(2003)107 cited
- → 5-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3)(2003)106 cited
- → Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers(2024)98 cited
- → 6-Heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3)(2003)85 cited
- → Conformationally Restricted Indolopiperidine Derivatives as Potent CCR2B Receptor Antagonists(2001)44 cited
- → The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition(2022)43 cited
- → Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP‐TEAD Protein‐Protein Interaction Inhibitors(2023)22 cited